Figure 4.

Mouse C4-HD and CC4-3-HI and human IBH-4, IBH-6 and MDA-MB-231 tumour growth in vivo comparing the α₂-adrenoceptor antagonist rauwolscine (Rau) and the β₂-adrenoceptor agonist salbutamol (Salb). (A) Mouse progestin-dependent C4-HD tumour in the presence of MPA depot in Balb/c mice. (B) Mouse progestin independent CC4-3-HI in Balb/c mice. (C) Human IBH-4 tumour growing in nude mice. (D) Human IBH-6 tumour growing in nude mice. (E) MDA-MB-231 tumour growing in nude mice. The animals were daily injected with the following compounds: salbutamol (1.2 mg kg⁻¹ day⁻¹); rauwolscine: 0.5 mg kg⁻¹ day⁻¹ or (salbutamol + rauwolscine) at the same doses. The control group received physiological saline. *P < 0.05, **P < 0.01; with respect to control; n = 10 animals/group, anova followed by Tukey–Kramer test. Each experiment was repeated twice with similar results.